3 citations
,
July 2018 in “European Journal of Dermatology” An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.
June 2025 in “Dermatopathology” This study reports that SARS-CoV-2 infection, COVID-19 vaccination, and off-label dupilumab treatment may exacerbate psoriasis, with overlapping inflammatory pathways involving cytokines like IL-17 and TNF-α. Histopathological similarities between psoriasis flares and COVID-19 skin manifestations were noted, suggesting a potential connection requiring further research.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.
2 citations
,
April 2024 in “Anais Brasileiros de Dermatologia” Pre-existing skin conditions and drug reactions are the main causes of exfoliative erythroderma.
December 2023 in “Asian journal of medical sciences” This study from S.C.B. Medical College explored the clinico-etiological and histopathological patterns of erythroderma, observing psoriasis as the most common cause, followed by idiopathic cases and atopic or drug-induced dermatitis, highlighting the need for careful management and awareness of alternative medicine use.